RE:CAR-T updateFebruary 02, 2024 - The FDA has decided on a date for a highly anticipated advisory committee meeting to discuss applications for Bristol Myers' Abecma and Johnson & Johnson's Carvykti.
The FDA will convene its Oncologic Drugs Advisory Committee (ODAC) for a full-day meeting on March 15 to review the applications for Bristol Myers Squibb and 2seventy bio’s Abecma and J&J and Legend Biotech’s Carvykti in earlier treatment of multiple myeloma.
https://www.fiercepharma.com/pharma/fda-sets-date-high-profile-car-t-adcomm-bristols-abecma-jjs-carvykti